Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Prague, Czechia, 140 59
- Xentria Investigative Site
-
-
-
-
-
Aalborg, Denmark, 9000
- Xentria Investigative Site
-
Aarhus, Denmark, 8200
- Xentria Investigative Site
-
Odense, Denmark, 5000
- Xentria Investigative Site
-
Roskilde, Denmark, 4000
- Xentria Investigative Site
-
Vejle, Denmark, 7100
- Xentria Investigative Site
-
-
-
-
-
Bielsk Podlaski, Poland, 15-044
- Xentria Investigative Site
-
Lodz, Poland, 90-153
- Xentria Investigative Site
-
-
-
-
-
Barcelona, Spain, 08035
- Xentria Investigative Site
-
Barcelona, Spain, 08036
- Xentria Investigative Site
-
Seville, Spain, 41013
- Xentria Investigative Site
-
-
-
-
England
-
Coventry, England, United Kingdom, CV22DX
- University Hospitals Coventry and Warwickshire NHS Trust
-
London, England, United Kingdom, SE59RS
- King's College Hospital NHS Foundation Trust
-
London, England, United Kingdom, NW12PG
- University College London Hospitals NHS Foundation Trust
-
Norwich, England, United Kingdom, NR47UY
- Norfolk and Norwich University Hospitals NHS Foundation Trust
-
Oxford, England, United Kingdom, OX37LE
- Oxford University Hospitals NHS Foundation Trust
-
-
Scotland
-
Perth, Scotland, United Kingdom, PH11NX
- NHS Tayside
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Xentria Investigative Site
-
-
Colorado
-
Denver, Colorado, United States, 80206
- Xentria Investigative Site
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- Xentria Investigative Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Xentria Investigative Site
-
Chicago, Illinois, United States, 60612
- Xentria Investigative Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Xentria Investigative Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Xentria Investigative Site
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Xentria Investigative Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Xentria Investigative Site
-
-
New York
-
Albany, New York, United States, 12208
- Xentria Investigative Site
-
New York, New York, United States, 10029
- Xentria Investigative Site
-
-
North Carolina
-
Greenville, North Carolina, United States, 27858
- Xentria Investigative Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Xentria Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Xentria Investigative Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Xentria Investigative Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Xentria Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant between 18 to 80 years (inclusive) of age.
- Weighs between 45 kg and 160 kg (99 to 353 lbs) at Screening.
- Diagnosis of pulmonary sarcoidosis (at least 6 months before Screening) using the 2020 American Thoracic Society (ATS) Clinical Practice Guideline (Crouser et al, 2020), the European Respiratory Society (ERS) or the WASOG criteria including a compatible clinical and radiologic presentation with other causes of granulomatous disease ruled out (cutaneous and ocular involvement permitted).
- Modified Medical Research Conference (mMRC) Dyspnea Scale of ≥ 1.
- Receiving treatment of 7.5 to 25 mg/day of oral prednisone, or equivalent, during the screening period and, at the determination of the investigator, is capable of undergoing the protocol specific corticosteroid taper regimen.
- Receiving treatment with methotrexate, azathioprine, mycophenolate, leflunomide, chloroquine, or hydroxychloroquine for at least 3 months before Screening that has been at a stable dose for 4 weeks before Screening. All efforts should be made to maintain stable background therapy at the Screening dose through the intervention period at the Investigator's discretion.
- Willing to refrain from consumption of grapefruit or grapefruit juice [pomelos, exotic citrus fruits, or grapefruit hybrids] from screening visit until after the final dose.
- Polymerase chain reaction (PCR) test or rapid antigen test negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening.
- Able to provide written informed consent.
- In the opinion of the Investigator, the participant is capable of understanding and complying with protocol requirements
Exclusion Criteria:
-
Pregnant or breastfeeding women or women who are planning to become pregnant during the study.
-
Participants > 65 years of age. (This exclusion criterion is only applicable for EU).
-
Known potentially significant fibrotic disease and/or active inflammation contained solely in the hilar region as shown by high-resolution computed tomography (HRCT), confirmed by a central reader. Participants with current active inflammation in the hilar region with concurrent inflammation outside the hilar region may be included.
A historical HRCT performed within 6 months of screening may be submitted for diagnostic confirmation by central review. If a subject's last HRCT was from > 6 months of screening, an HRCT should be performed during screening for diagnostic confirmation by central review.
-
Any prior TNFα inhibitor therapy.
-
Clinically significant extra-pulmonary sarcoidosis requiring systemic therapy as determined by the investigator.
-
Baseline percent predicted forced vital capacity (FVC) of < 50%.
-
Prior treatment with rituximab or repository corticotropin injection within the previous 12 months.
-
Clinically significant Central Nervous System (CNS) sarcoidosis requiring therapy, except history of isolated seventh cranial nerve palsy or evidence of demyelinating neurologic disease.
-
Advanced congestive heart failure (New York Heart Association [NYHA] 3 or 4).
-
Current disease presentation consistent with Lofgren's syndrome (i.e., presence of the triad of erythema nodosum, bilateral hilar lymphadenopathy on chest X-ray, and joint pain).
-
Clinically significant pulmonary hypertension requiring treatment. Note: Clinically significant pulmonary hypertension requiring treatment would be defined as treatment with, i.e., prostacyclins, phosphodiesterase 5 inhibitors, and endothelin receptor antagonists.
-
Known hypersensitivity to any component of the formulation of XTMAB-16.
-
Live or messenger ribonucleic acid (mRNA) vaccination within 2 weeks before Day 1 or inoculation with a live or mRNA vaccine is planned during study participation.
-
Evidence of active or latent TB by interferon-gamma release assay (IGRA) or invasive fungal infections at Screening.
-
Known positive history of malignancy other than non-melanomatous skin cancer in the last 2 years, including in-situ carcinoma of the uterine cervix completely cured by radical surgery.
-
Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, coronavirus disease (COVID-19), TB, or a known history of human immunodeficiency virus (HIV) infection at Screening.
-
Women of childbearing potential who are sexually active with a non-sterilized male partner and are not willing to adhere to highly effective birth control measures from the time of signing the informed consent, throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since the last dose of study drug.
-
Male participants who are non-sterilized and sexually active with a female partner of childbearing potential and are not willing to use highly effective contraception from the time of signing the informed consent throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since last dose of study drug.
-
Clinically significant hepatic or renal disease, including uncontrolled diabetes at the discretion of the investigator.
-
Any severe prior reaction to any type of biologics or human blood product such as albumin, IgG, etc.
-
Concurrent emphysema.
-
Known hypercalcemia due to non-sarcoidosis conditions such as untreated hyperparathyroidism, at the discretion of the investigator.
-
Abnormal ECG: ventricular arrhythmias (non-sustained ventricular tachycardia (VT), multifocal or frequent premature ventricular contractions, bundle branch block, axis deviation, or abnormal Q waves). In the case of a QTcF (corrected QT interval by Fredericia) interval > 450 ms (men) or > 480 ms (women; participants with bundle branch block) or PR interval outside the range of 120 to 220 ms, the assessment may be repeated once for eligibility determination at Screening or Baseline.
-
Donation or loss of 450 mL or more of his or her blood volume (including plasmapheresis) or transfusion of any blood product within 90 days prior to dosing.
-
Known uncontrolled hypertension. Note: Uncontrolled hypertension is noted as blood pressure ≥ 160/100 mmHg despite antihypertensive therapy within 3 months of randomization.
-
Clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, sore throat, fatigue, new smell or taste disorder or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening.
-
In the opinion of the investigator, inability to tolerate corticosteroid taper.
-
Concurrent systemic steroid use for non-sarcoidosis conditions.
-
Concurrent known auto-immune disease requiring treatment.
-
Participation in another clinical trial of an investigational agent within 3 months (small molecule) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer.
-
Any condition that required hospitalization within the 3 months prior to Day 1 or is likely to require so during the study.
-
Clinically significant abnormalities in the Screening physical exam, medical history, vital signs, ECG, or clinical laboratory tests that are not known to be due to concurrent sarcoidosis, and in the opinion of the Investigator and Medical Monitor should preclude the participant's participation in the clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part A - XTMAB-16: 2 mg/kg every 4 weeks (Q4W) for 12 weeks or Placebo
|
Infusion |
|
Experimental: Part A - XTMAB-16: 4 mg/kg every 4 weeks (Q4W) for 12 weeks or Placebo
|
Infusion |
|
Experimental: Part A - XTMAB-16: 2 mg/kg every 2 weeks (Q2W) for 12 weeks or Placebo
|
Infusion |
|
Experimental: Part A - XTMAB-16: 4 mg/kg every 2 weeks (Q2W) for 12 weeks or Placebo
|
Infusion |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of Adverse Events (AEs), including Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs), and Adverse Events of Special Interests (AESIs) throughout the study duration
Time Frame: Throughout Study Duration, 20 weeks
|
To evaluate the safety and tolerability of multiple ascending doses of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Throughout Study Duration, 20 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic (PK) profile including trough concentration (Ctrough)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Pharmacokinetic (PK) profile including maximum concentration (Cmax)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Pharmacokinetic (PK) profile including average concentration (Caverage)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Pharmacokinetic (PK) profile including area under the curve (AUC)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Dose normalized maximum serum concentration (Cmax/D)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Dose normalized area under the concentration time curve over the dosing interval (AUCtau/D)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Dose normalized area under the concentration time curve from time 0 to the time of the last quantifiable concentration observed (AUClast/D)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Dose normalized area under the concentration time curve from time 0 extrapolated to infinity (AUCinf/D)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Pharmacodynamics (PD) markers, including: Angiotensin converting enzyme (ACE), Soluble IL-2 receptor (sIL 2R), C-reactive protein (CRP), Interleukin-1b (IL-1b) and Calcitriol (vitamin D 1, 25)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Occurrence and persistence of anti-drug antibodies (ADA)
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Mean percent change in forced vital capacity (FVC)%
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Change in King's Sarcoidosis Questionnaire (KSQ) - Lung Score
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
The King's Sarcoidosis Questionnaire (KSQ) - General Health. Results are given as a number between 1 to 100 with higher numbers indicating better health. The minimal clinically important difference (MCID) for KSQ remains unclear in sarcoidosis.
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
The Leicester Cough Questionnaire items are scored on a 7-point Likert scale. A total score (range 3 to 21) is also calculated by adding the domain scores together, with higher scores indicating better quality of life. The MCID for chronic cough is 1.3.
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
The Steroid Toxicity Questionnaire (STQ) is a simple 12 question tool used to characterize the toxicity associated with steroid use using a 4-point scale. The MCID remains unclear in sarcoidosis. Higher scores indicate greater steroid toxicity
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Observed dose limiting toxicities (DLT), rate of adverse events of special interest (AESI) throughout the study duration between dose levels and frequencies
Time Frame: Baseline to Week 12
|
To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Proportion of participants who achieve the targeted tapered dose of corticosteroid
Time Frame: Baseline to Week 12
|
To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use |
Baseline to Week 12
|
|
Proportion of participants who achieve at least 50% reduction in dose of corticosteroid by Week 12
Time Frame: Baseline to Week 12
|
To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use |
Baseline to Week 12
|
|
Total (systemic) clearance after intravenous (IV) dose in the intended participant population
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Volume of distribution after intravenous (IV) dose and an estimate of the volume of distribution at steady state based on single dose IV data parameters in the intended participant population
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Terminal elimination phase half-life expressed in time units in the intended participant population
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Accumulation ratio repeat dosing
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Area under the effect-time curve from time 0 (predose) to the last quantifiable effect -concentration time point, t (AUEC0-t)
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Maximum observed effect (Emax, obs)
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Time to reach Emax, obs (tEmax, obs)
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Absolute and percent change in biomarkers from Baseline to End of Infusion (EOI), Interleukin-6 (IL-6) and Soluble Tumor Necrosis Factor α (sTNFα)
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Number and percentage of participants by cohort who test positive for XTMAB-16 anti-drug antibodies (ADA) and transient & persistent positive status at follow-up assessments
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
|
Number and percentage of participants by cohort who test positive for XTMAB-16 neutralizing antibody (nAb) and transient & persistent positive status at follow-up assessments
Time Frame: Baseline to Week 12
|
To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations |
Baseline to Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- XTMAB-16-201 Part A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.